Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2020 - 12 - 08 save search
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Published: 2020-12-08 (Crawled : 22:00) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy treatment designation
Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury
Published: 2020-12-08 (Crawled : 19:01) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: 3.77%
H: 0.0%
C: -1.21%
therapy spinal cord treatment
Panbela Therapeutics, Inc. Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer· Phase 1b Data Expected 1H 2021
Published: 2020-12-08 (Crawled : 16:01) - biospace.com/
PBLA | $0.4895 -6.31% 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.94%
cancer therapy trial pancreatic phase 1b pancreas phase 2b enroll
Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
Published: 2020-12-08 (Crawled : 16:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.13%
H: 0.04%
C: -0.03%
cancer therapy lung cancer breakthrough therapy grant designation
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
Published: 2020-12-08 (Crawled : 14:05) - globenewswire.com
MNPR | $0.636 -6.19% -6.6% 33K
|
Health Technology
|
| O: -4.06%
H: 12.8%
C: 11.97%
cancer therapy trial oral mucositis phase 2b
Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities
Published: 2020-12-08 (Crawled : 14:02) - globenewswire.com
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 1.11%
H: 1.6%
C: -2.84%
license therapy disease kidney diseases kidney
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
Published: 2020-12-08 (Crawled : 14:02) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy tyrosine kinase inhibitor designation
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
Published: 2020-12-08 (Crawled : 12:01) - globenewswire.com
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: 2.09%
H: 1.15%
C: -1.53%
therapy gene therapy trial gene therapies
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
Your saved searches
Save your searches and get alerts when important news are released.